Reinforcer pathology, probabilistic choice, and medication adherence in patients with multiple sclerosis

Area of Science:

• Behavioral economics
• Health psychology
• Neuroscience

Background:

• The reinforcer pathology model links behavioral economic mechanisms to adverse health decisions.
• Current applications primarily focus on substance use disorder and obesity.
• Limited research exists on applying this model to medication adherence.

Purpose of the Study:

• To evaluate medical adherence decisions in multiple sclerosis (MS) patients using a reinforcer pathology framework.
• To examine the relationship between behavioral economic measures and adherence to disease-modifying therapies.
• To assess the influence of side effect risk and efficacy on treatment decisions.

Main Methods:

• Participants with multiple sclerosis completed behavioral economic assessments.
• Measures included delay discounting, probability discounting, and a medication purchase task.
• A hypothetical medication decision-making task assessed sensitivity to risk and efficacy.

Main Results:

• Steeper delay discounting and lower medication demand were associated with poorer adherence.
• Behavioral economic metrics were independently linked to adherence decisions.
• Interactions between general and medication-specific metrics supported the reinforcer pathology model.

Conclusions:

• Behavioral economic principles, specifically delay discounting and medication demand, are crucial in understanding and predicting medication adherence in multiple sclerosis.
• Findings support the expansion of the reinforcer pathology model to positive health behaviors like medication adherence.
• Further research is needed to generalize these findings to diverse populations and health behaviors.